Browse by Profession PharmaciesHospitalsDoctorsPatientsManufacturers

Place an Order

News for doctors

Healthcare Distribution Management Association (HDMA)

Masters Medical Inc (MMI) based in Florida is pleased to announce that it has become a member of the Healthcare Distribution Management Association (HDMA). This affliliation will provide additional resource to further strengthen the Masters supply chain and enhance the services we provide to our valued customers.

Masters, focused on providing the Patient, wherever they are, access to the best available treatments.

 
  
Master . . ,


Systemic Mastocytosis and Mast Cell Activation Syndrome - sodium cromoglicate 100mg Tablets

Masters Pharmaceuticals Ltd is pleased to announce the availability of sodium cromoglicate 100mg Tablets for the alleviation of the symptoms of Systemic Mastocytosis and Mast Cell Activation Syndrome.
Please see the information below regarding supply:


LORAZEPAM Injection 4mg/ml - Available from Masters Pharmaceuticals Limited.

Masters Pharmaceuticals Limited in the United Kingdom is pleased to announce the availability of Lorazepam Injection 4mg/mL.

Presentation: Lorazepam Injection 4mg/mL is supplied as 1mL vials in packs of 25

 

Masters recognises the importance of the role that Doctors play in creating access to potentially life-saving medicines, especially when the supply of a particular drug may not be available in some countries. By working with Masters, Doctors benefit from both its Global Reach and NPS experience, allowing them to prescribe unlicensed medicines from all over the wolrd, which may be:

  • Awaiting registration
  • Have been discontinued
  • Are in a Clinical Trial
Masters provides the vital link between Doctors and Manufacturers, enabling Doctors to fulfil their patients' unmet medical needs, by providing the best treatments available for a particular diease. In this respect, we offer doctors greater choice, flexibility and scope in providing treatments that fall outside conventional prescribing routes, particularly for patients who have exhausted other therapeutic means.

We understand that Doctors need appropriate support and information to be able to develop a comprehensive Named Patient Supply programme, which is why we offer such a personal service, providing support throughout the Named Patient Supply Programme.

Masters will also take care of various aspects of the program on behalf of the Doctors, including the following:

  • Dosing
  • Administration & Restrictions
  • Treatment and Care Protocols to ensure proper selection of patients

Masters provides Doctors with key market intelligence and helps them build relations with key opinion leaders and other doctors who may be likely prescribers once a drug is registered. By participating in such programmes, doctors will not only gain valuable experience of a drug before registration, but may also be important resources for regulators and other local healthcare providers.

For more information on NPS programmes provided by Masters, simply refer to the following link:
 

  • Named patient supply (NPS)

  • Named patient supply, also known as expanded access programmes (EAP), enables doctors to prescribe drugs that cannot be obtained through traditional prescribing channels.
  • Click here to learn more about Masters' NPS programme.